Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple test predict CAR t success? new study hopes to find out

NCT ID NCT07472972

Knowledge-focused Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new combination of blood tests, scans, and health checks to see if it can predict which lymphoma patients will respond well to CAR T cell therapy. Researchers will follow 50 patients with relapsed or hard-to-treat B-cell lymphoma who are already scheduled for standard CAR T treatment. The main goal is to see if the full test can be completed for each patient, not yet to change treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this tool could help doctors choose the best treatment for each lymphoma patient before starting CAR T therapy.
What could go wrong
This is a small, early feasibility study (50 participants) focused on whether the test can be completed, not yet on improving outcomes. The tool may not accurately predict responses in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes patients with lymphoid malignancies receiving anti-CD19 CAR T-cell therapy. This population is at high risk for disease progression. 50 patients in total will be enrolled in the study. The study does not include an additional control group but the risk analysis in arm B will be performed with blinding to the patient outcome. We expect to have a balanced sex proportion within our trial.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent before registration and prior to any trial specific procedures * Participants ≥ 18 years of age * Diagnosis of relapse/refractory B-cell lymphoma according to WHO 2022 classification * Measurable disease per response criteria specific to the disease e.g. per Lugano 2014 criteria * Patients planned for CD19-redirected CAR T cell therapy according to clinical standard of care * Patients who are willing to donate peripheral blood and biopsy material at indicated clinical visits Exclusion Criteria: * Any condition, which precludes initiation of CD19-redirected CAR T cell therapy (e.g. breast feeding, pregnancy, infections, etc.) as judged by the treating physician * Any coexisting medical or psychological condition that would preclude participation in the required study procedures, as judged by the treating physician * Unwillingness or inability to comply with the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphoid hematological malignancies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma lymphoid neoplasm lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoid hematological malignancies Lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Universityhospital Zurich, Department of Medical Oncology and Hematology

    RECRUITING

    Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.